| RELMADA THERAPEUT.DL-,001 |
| USA |
| Gesundheit |
| US75955J4022 / A2PSZF |
| 4E2 (Frankfurt) / RLMD (NASDAQ) |
| FRA:4E2, ETR:4E2, 4E2:GR, NASDAQ:RLMD |
| - |
| https://www.relmada.com/ |
|
Relmada Therapeutics Inc. is a clinical-stage biot..
>Volltext.. |
| 111.52 Mio. EUR |
| 94.09 Mio. EUR |
| - |
| -60.6 Mio. EUR |
| -58.27 Mio. EUR |
| -1.9 EUR |
| - |
| 1.16 Mio. EUR |
| -42.9 Mio. EUR |
| 4.02 |
| - |
| 28.94% |
| - |
| - |
| - |
| RELMADA |
| 14.11.25 |
|